Norway· NO-ID_F17F5358-2755-44B0-B584-2E93CAE005BC
Rivaroxaban Sandoz
A rivaroxaban product containing rivaroxaban, registered in Norway by Sandoz - København. The same ATC class is registered in 15 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Rivaroxaban is registered in 15 of 19 countries.
Countries holding a registration under ATC B01AF01 (rivaroxaban), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 9 of them publish a price we can compare per daily dose
Rivaroxaban · ATC B01AF01
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of rivaroxaban costs, country by country.
Normalised to the WHO defined daily dose (20 mg), the median price runs from $0.67 in France to $5.20 in United States — a ×7.7 gap.
- 4 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Rivaroxaban · price per daily dose (20 mg)
USD · FX 28 Sept 2026
- US United States$5.20 (acquisition cost)
- CH Switzerland$2.66
- IT Italy$1.08
- FR France$0.67
The record
At a glance
FEST (Norway)- Active substance
- Rivaroxaban
- Manufacturer
- Sandoz - København
- Country
- Norway (NO)
- ATC code
- B01AF01
- ATC class
- Rivaroxaban
- Defined daily dose
- 20 mg, O
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 19
9 priced- no_varenummer49433310NOK 197.6
- no_varenummer40005528NOK 488.1
- no_varenummer54637614NOK 262.2
- gtin7622436100920
- gtin7622436100852
- gtin7622436101194
- gtin7622436102375
- no_varenummer11410098NOK 1617.6
- no_merkevare_idID_F17F5358-2755-44B0-B584-2E93CAE005BC
- no_varenummer14062298NOK 1617.6
- no_varenummer38028310NOK 197.6
- no_varenummer48984428NOK 488.1
- no_varenummer445274112NOK 1843.5
- no_varenummer47784014NOK 262.2
- gtin7622436145372
- gtin7622436145358
- gtin7622436145341
- gtin7622436102917
- gtin7622436145334
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
391 interactions on record for rivaroxaban.
Graded by severity as the source publishes them — 134 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Rivaroxaban · interactions on record
391 records
- 134 severe
- 213 moderate
- 2 minor
Most severe, free to view
- LonafarnibA16AX20severe
- DicoumarolB01AA01severe
- WarfarinB01AA03severe
- HeparinB01AB01severe
42 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Rivaroxaban in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaAXALTRA+pharma arzneimittel gmbh, Graz
- SpainCOAGUBAN 10 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGTowa Pharmaceutical Europe S.L.
- PolandAxaltrapharma arzneimittel gmbh
- SwitzerlandRivarax 10 mg, FilmtablettenDrossapharm AG
- NetherlandsBlomensy 10 mg filmomhulde tablettenEgis Pharmaceuticals Plc
- SwedenBevimlar 10 mg Filmdragerad tablettSTADA Arzneimittel AG
- FinlandDovequaBausch Health Ireland Limited
- ItalyMIREBAXAURORA LICENSING S.R.L.
Authorised across Europe · EMA
The same active substance is authorised in 30 EEA countries. Names it is sold under:
- Austria · Rivahib, Rivaroksaban Grindeks
- Belgium · Rivaroxaban, Rivaroxaban Eg
- Bulgaria · Xaboplax Sandoz Pharmaceuticals D.D, Виатрикс
- Cyprus · Enkia, Naxat
- Czechia · Axaltra, Bevimlar
- Germany · Elmardya, Rivadia
- Denmark · Blomensy, Dovequa
- Estonia · Enkia, Kardatuxan
- Spain · Blomensy, Elmardya
- Finland · Blomensy, Dovequa
- France · Elmardya, Rivaroxaban Almus
- United Kingdom (Northern Ireland) · Rivaroxaban, Rivaroxaban Abdi
- Greece · Blomensy, Cinstel
- Croatia · Aban, Bevimlar
- Hungary · Dovequa, Evoxyr
- Ireland · Rivaroxaban Ascend, Rivaroxaban Azure
- Iceland · Agublon, Barsovi
- Italy · Ellebax, Indifaxa
- Liechtenstein · Rivaroxaban Accord, Rivaroxaban Viatris
- Lithuania · Enkia, Kardatuxan
- Luxembourg · Rivaroxaban Eg, Rivaroxaban Eg (Eurogenerics) Nv
- Latvia · Kardatuxan, Mibrex
- Malta · Enkia, Naxat
- Netherlands · Blomensy, Rivaroksaban Grindeks
- Poland · Axaltra, Bevimlar
- Portugal · Closderive, Enkia
- Romania · Closderive, Enkia
- Sweden · Bevimlar, Blomensy
- Slovenia · Dovequa, Ribas
- Slovakia · Assubex, Bevimlar
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c13a2d17-6eed-45b9-b603-67f9c563eebf GET /v1/drugs/c13a2d17-6eed-45b9-b603-67f9c563eebf?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tablett, filmdrasjert",
"source": "fest",
"status": "A",
"atc_name": "Rivaroksaban",
"merkevare_id": "ID_F17F5358-2755-44B0-B584-2E93CAE005BC",
"name_form_strength": "Rivaroxaban Sandoz tab 10 mg",
"prescription_group": "C"
}See everything about rivaroxaban.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.